- Home
- AACG vs CELU Comparison
AACG vs CELU Comparison
Compare AACG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- CELU
- Stock Information
- Founded
- AACG 1999
- CELU 2016
- Country
- AACG China
- CELU United States
- Employees
- AACG N/A
- CELU N/A
- Industry
- AACG Other Consumer Services
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- CELU Health Care
- Exchange
- AACG Nasdaq
- CELU Nasdaq
- Market Cap
- AACG 51.9M
- CELU 56.9M
- IPO Year
- AACG N/A
- CELU N/A
- Fundamental
- Price
- AACG $1.09
- CELU $1.96
- Analyst Decision
- AACG
- CELU Strong Buy
- Analyst Count
- AACG 0
- CELU 1
- Target Price
- AACG N/A
- CELU $6.00
- AVG Volume (30 Days)
- AACG 23.8K
- CELU 69.1K
- Earning Date
- AACG 11-12-2025
- CELU 11-14-2025
- Dividend Yield
- AACG N/A
- CELU N/A
- EPS Growth
- AACG N/A
- CELU N/A
- EPS
- AACG N/A
- CELU N/A
- Revenue
- AACG $39,316,403.00
- CELU $40,578,000.00
- Revenue This Year
- AACG N/A
- CELU N/A
- Revenue Next Year
- AACG N/A
- CELU $76.00
- P/E Ratio
- AACG N/A
- CELU N/A
- Revenue Growth
- AACG 11.62
- CELU N/A
- 52 Week Low
- AACG $0.70
- CELU $1.00
- 52 Week High
- AACG $2.58
- CELU $4.35
- Technical
- Relative Strength Index (RSI)
- AACG 43.43
- CELU 57.50
- Support Level
- AACG $1.18
- CELU $1.62
- Resistance Level
- AACG $1.36
- CELU $2.29
- Average True Range (ATR)
- AACG 0.11
- CELU 0.15
- MACD
- AACG -0.00
- CELU 0.06
- Stochastic Oscillator
- AACG 33.33
- CELU 63.29
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.